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Association between genetic risk scoring for schizophrenia and
bipolar disorder with regional subcortical volumes
X Caseras1, KE Tansey1,2, S Foley1,3 and D Linden1,3
Previous research has shown coincident abnormal regional brain volume in patients with schizophrenia (SCZ) and bipolar disorder
(BD) compared with controls. Whether these abnormalities are genetically driven or explained by secondary effects of the disorder
or environmental factors is unknown. We aimed to investigate the association between genetic risk scoring (GRS) for SCZ and BD
with volume of brain areas previously shown to be different between these clinical groups and healthy controls. We obtained
subcortical brain volume measures and GRS for SCZ and BD from a sample of 274 healthy volunteers (71.4% females, mean age 24.7
(s.d. 6.9)). Volume of the globus pallidus was associated with the shared GRS between SCZ and BD, and also with the independent
GRS for each of these disorders. Volume of the amygdala was associated with the non-shared GRS between SCZ and BD, and with
the independent GRS for BD. Our results for volume of the globus pallidus support the idea of SCZ and BD sharing a common
underlying neurobiological abnormality associated with a common genetic risk for both these disorders. Results for volume of the
amygdala, though, would suggest the existence of a distinct mechanism only associated with genetic risk for BD. Finally, the lack of
association between genetic risk and volume of most subcortical structures suggests that the volumetric differences reported in
patient–control comparisons may not be genetically driven, but a consequence of the disorder or co-occurring environmental
factors.
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INTRODUCTION
Recent neuroimaging research has shown bipolar disorder (BD) to
be associated with brain structural abnormalities. Different meta-
analytical efforts have shown presence of enlarged lateral
ventricles and globus pallidus and reduced prefrontal volume in
BD patients compared with healthy controls.1–3 More recently,
the ENIGMA (Enhancing NeuroImaging Genetics through
Meta-Analysis) consortium has performed the largest study of
subcortical brain volumes in BD to date—over 1500 patients and
2500 controls—replicating the enlargement of lateral ventricles in
patients with BD, but not that of the globus pallidus, and also
reporting decreased volume of the thalamus, amygdala and
hippocampus.4
Overlapping results have been reported in structural brain
imaging studies of schizophrenia (SCZ). In a meta-analysis of 58
studies, Wright et al.5 found evidence in SCZ for enlarged lateral
ventricles and globus pallidus, and reduced volume of amygdala,
hippocampus, thalamus and caudate. The ENIGMA consortium,
with a sample of over 2000 cases and controls, also reported
enlarged lateral ventricles and globus pallidus, and reduced
volumes of amygdala, hippocampus, thalamus and accumbens.6
Fewer studies have compared participants diagnosed with BD
and SCZ directly, but the results of those point again towards a
very important coincidence in subcortical and cortical gray matter
abnormalities between both disorders, with SCZ being associated
with more extensive abnormalities and greater effect sizes3,7,8 and
therefore suggesting the differences between both these dis-
orders being quantitative rather than qualitative. This
correspondence in brain anatomical abnormalities is not surpris-
ing considering the important overlap between both disorders in
terms of their clinical presentation and associated cognitive
deﬁcits.9,10 Moreover, recent genetic research has also highlighted
a substantial overlap in common genetic variation associated with
both disorders.11,12 These results question the classical division set
by Kraepelin more than a century ago between the two types of
psychosis, suggesting that both disorders might represent
differences in the intensity of phenotype alterations caused by
the same underlying neurobiological mechanisms.
However, whether the aforementioned anatomical abnormal-
ities predate the onset of the disorder, are a consequence of it, or
perhaps reﬂect pharmacological effects of the treatment that
these patients commonly receive, is a key question that remains
unanswered. It is frequently assumed that if predating the
disorder, these abnormalities would arise from genetic factors,
but it could also be the case that they reﬂect exposure to
environmental factors that contribute to both disorders. To
address this issue, some studies have included non-affected
relatives of BD and SCZ patients in their design.13–15 Here, the
premise is that the unaffected relatives of people with the
disorder are at higher genetic risk than the population average
but are not subject to secondary effects of the disorder itself
(including its treatment). Consequently, if the unaffected relatives
have similar abnormalities to cases, it can be concluded that these
are more likely to be genetically driven than environmentally or
pharmacologically caused. However, to date these studies have
mostly failed to replicate the aforementioned coincidence in
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anatomical abnormalities between SCZ and BD, most likely due to
their smaller sample sizes and the consequent limitation in
statistical power.
Developments in genetics have recently allowed a new method
for investigating the relationship between genetic risk and brain
volumes that relies on a quantitative direct measurement of risk
rather than categorical stratiﬁcation by family history. This
method, known as genetic risk scoring (GRS), uses risk alleles
derived from genome-wide association studies (GWAS) studies to
quantify the common risk allele burden carried by individuals for a
given disorder based on the average number of independent risk
alleles, weighted by their effect size. In the present study, we
aimed to investigate the association between the volumes of brain
regions previously shown to be abnormal in SCZ and BD (that is,
thalamus, amygdala, hippocampus, globus pallidus, caudate and
lateral ventricles) and GRS for both these disorders in a large
sample of healthy participants with no history of mental disorders
and free of any psychotropic medication. Assuming that structural
brain abnormalities reported in BD and SCZ are consequences of
genetic risk factors that are common to both disorders, we predict
the volume of these subcortical areas to be associated with the
shared genetic risk for both disorders, and less so with their
distinct genetic risk. The fact that the sample only includes
participants with no personal history of BD or SCZ precludes any
secondary inﬂuences of disease course or treatment on brain
volume.
MATERIALS AND METHODS
Participants
Brain scans used in this study were obtained from a repository of
neuroimaging and genetic data obtained between 2009 and 2014 from
healthy subjects recruited at Cardiff University Brain Research Imaging
Centre (CUBRIC). The original sample consisted of 319 individuals that
contributed neuroimaging and genetic data. Participants were recruited if
they had no current or past history of psychiatric disorders according to
clinical screening, were aged between 18 and 55, and had no history of
neurological or medical conditions that could have affected brain anatomy
or incurred a scanning risk (for example, head trauma, epilepsy, cardiac
conditions).
Genotyping and quality control
Genomic DNA was obtained from saliva using Oragene OG-500 saliva kits
(DNA Genotek, Kanata, ON, Canada). Genotyping was performed using
custom Illumina HumanCoreExome-24 BeadChip genotyping arrays that
contained probes for 5 70 038 genetic variants (Illumina, San Diego, CA).
Quality control was implemented in PLINK.16 Individuals were excluded for
any of the following reasons: (1) no match between reported and
molecular sex; (2) cryptic relatedness of up to third degree relatives as
ascertained using identity by descent; (3) genotyping completeness
o97%; (4) and non-European ancestry. The latter was detected as outliers
in iterative EIGENSTRAT analyses of a linkage disequilibrium pruned data
set.17 Single nucleotide polymorphisms (SNPs) were excluded for any of
the following reasons: (1) minor allele frequency o1%; (2) genotype call
rate o98%; and (3) Hardy–Weinberg equilibrium P-valueo1e− 04.
Genotypes were imputed using the pre-phasing/imputation stepwise
approach implemented in IMPUTE2/SHAPEIT18,19 and 1000 Genomes
(December 2013, release 1000 Genomes haplotypes Phase I integrated
variant set) as the reference data set.
After quality control, the sample was reduced to 274 participants (195
(71.4%) females, mean age 24.77 (s.d. 6.86)). About 2 96 832 genotyped
SNPs passed quality controls and resulted in a data set of 74 13 342
imputed SNPs.
MRI data acquisition and processing
All magnetic resonance imaging (MRI) data were acquired in a GE Sigma
HD×3T scanner (GE Healthcare, Milwaukee, WI, USA) at CUBRIC.
Anatomical images of the brain consisted of 3D fast spoiled gradient
echo images obtained at TR= 7.9 ms, TE = 3.0 ms, inversion time= 450ms,
ﬂip angle = 20, acquisition matrix = 256 (AP) × 192 (LR) × 172 (SI), 1 mm
isotropic voxels.
Brain images were automatically segmented using FreeSurfer software
(http://surfer.nmr.mgh.harvard.edu) and the resulting outputs quality
controlled following a publically available protocol from ENIGMA (http://
enigma.ini.usc.edu/). Whenever a region-of-interest (ROI) was detected as
inadequately segmented, its metric was declared missing and excluded
from the analysis.
Genetic risk score
GRS methodology follows the procedure described by the International
Schizophrenia Consortium.11 We calculated GRS using the results from four
GWAS as our training data sets: (1) SCZ and BD cases versus controls
(GRS-SCZ&BD);20 (2) SCZ cases versus BD cases (GRS-SCZvsBD);20 (3) SCZ
cases versus controls (GRS-SCZ);21,22 and (4) BD cases versus controls
(GRS-BD).22,23 For the GRS-SCZ and GRS-BD, we used results generated by
the Cross-Disorder Group of the Psychiatric Genomics Consortium (PGC),22
which removed any overlapping controls from the data sets, ensuring the
data sets were completely independent. Despite the existence of recent
larger GWAS data for SCZ, for consistency we calculated the GRS-SCZ from
the initial iterations of the PGC data for SCZ.21 The main focus of our
analysis are the composite scores GRS-SCZ&BD and GRS-SCZvsBD and
those are only available from the initial iterations of the PGC data; likewise,
currently GRS-BD can only be obtained from the initial iteration of the
PGC data.
For all analyses, SNPs were removed if they had a low minor allele
frequency (MAFo0.01), and were subsequently pruned for linkage
disequilibrium using the (r2o0.25) clumping function (—clump) in
PLINK16 removing SNPs within 500 kb (—clump-kb) and r240.25
(—clump-r2) with a more signiﬁcantly associated SNP. We used the score
command in PLINK to calculated GRS,16 which were calculated by
summing the number of susceptibility alleles of each index SNP weighted
by the logarithm of the SNP odds ratios. Six P-value thresholds
(PTo1× 10− 5, 1 × 10− 4, 0.01, 0.1, 0.3, 0.5) for SNP association were used.
Association analyses
All subcortical volumes (averaged left and right hemispheres) and GRS
considered here followed the normal distribution. GRS were entered as
regressors of interest in linear regression analyses—after covariates have
been entered into the model—with gray matter volume of each ROI as
dependent variable. Age at scan only correlated with the volume of the
lateral ventricles and was therefore only included as covariate in the
analyses for this ROI. Gender and intracranial volume showed signiﬁcant
association with volume of all the ROIs considered here and were included
as covariates in all subsequent analyses. According to our hypotheses, we
investigated ﬁrst the association of GRS-SCZ&BD and GRS-SCZvsBD with
volume of the preselected ROIs. Where signiﬁcant effects were found, we
investigated the association with the disorder-speciﬁc GRS (that is GRS-SCZ
and GRS-BD) to ascertain that the effect was not driven by the sole
association with one of the phenotypes. Based on Sham and Purcell’s24
recommendations for multiple testing correction in dependent tests, we
applied a post hoc correction for multiple comparisons by performing
10 000 permutations of each linear regression analysis resulting in a
nominal Po0.05. These were performed using R.25 The permuted P-value
was calculated as the total number of times a permutation resulted in a P-
value less than the observed P-value, divided by the number of
permutations. If the permuted P-value was Po0.05, then we considered
the association signiﬁcant after correction for multiple testing.
RESULTS
The GRS-SCZ&BD calculated at PTo0.01, 0.1, 0.3 and 0.5 was
negatively associated with volume of the globus pallidus. GRS-
SCZ&BD at PTo1 × 10− 4 was negatively correlated with volume of
the thalamus, although this did not survive correction for multiple
comparison (Table 1 and Figure 1). To ascertain whether this effect
in the globus pallidus was driven mainly by only one of the
phenotypes, the association between volume of this ROI and the
GRS-SCZ and GRS-BD was calculated. As shown in Table 2, the
volume of the globus pallidus showed signiﬁcant association with
both genetic scores at different PT levels.
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The GRS-SCZvsBD only showed signiﬁcant association—negative
correlation—when calculated at PTo1 × 10− 5 with volume of the
amygdala (Table 1 and Figure 1). Analyses with the disease-
speciﬁc scores revealed that volume of the amygdala was
negatively associated with GRS-BD but not with GRS-SCZ (Table 2).
DISCUSSION
This study aimed to investigate the relationship between
composite measures of genetic risk for SCZ and BD with the
volume of subcortical brain structures that have previously been
shown to differ between cases and controls in clinical samples of
SCZ and BD, in a sample of healthy participants. Our results
showed the volume of the globus pallidus to be associated with
the genetic risk for both these disorders. Interestingly, the
predictive value—change in variance explained (ΔR2)—of the
combined SCZ&BD GWAS on the volume of this structure was
larger than the predictive value of the risk for each disorder
considered separately. This suggests that the volume of the
globus pallidus is associated with genetic variants that inﬂuence
risk for both SCZ and BD, rather than with non-shared genetic
variants. Contrary, the volume of the amygdala was only
associated with genetic risk for BD; although in this case, fewer
associations with GRS calculated at different PT values were found,
making this ﬁnding less robust.
Previous research has shown the globus pallidus to be larger in
BD and SCZ patients compared with healthy controls.3,4,6 Here, we
show volume of this brain structure is negatively associated with
genetic risk for these disorders in a sample of healthy participants.
Given that our participants were un-medicated and did not suffer
from any psychiatric condition, this association could not be
mediated by secondary effects of these disorders, or by the effect
of psychotropic medication. Moreover, we show that the volume
of this brain structure is associated with that fraction of genetic
risk that is shared across BD and SCZ. Interestingly, we found an
inverse relationship between genetic risk for these disorders and
the volume of the globus pallidus; that is, the higher the risk
added by common genetic variants the smaller the volume of this
structure. Antipsychotic medication has shown to increase the
volume of basal ganglia structures.26 The ENIGMA consortium
results for BD4 show enlarged volume of the globus pallidus in
patients taking typical antipsychotics compared with healthy
controls and also compared with patients under other class of
drugs/no-drugs. Similarly, those taking atypical antipsychotics
showed enlarged volume than healthy controls and patients
under other class of drugs/no-drugs, albeit in this case not
reaching statistical signiﬁcance.4 The ENIGMA SCZ group also
showed that volume of the globus pallidus was positively
associated with illness duration.6 Summarizing, the present results
show volume of the globus pallidus to be associated with the
shared genetic risk for BD and SCZ; the fact that we ﬁnd an inverse
relationship while clinical studies show enlargement in clinical
samples relative to controls could be explained by the inﬂuence of
factors like illness duration or antipsychotic medication. This
stresses the need to cautiously interpret the results from any
comparisons between clinical and control samples, or studies of
joined clinical and healthy samples, where many factors asso-
ciated with the pathology might conceal the results.
Our results also suggest amygdala volume to be negatively
associated with genetic risk for BD, but not for SCZ. Although in
this case the association follows the expected direction—that is,
decreasing volume as genetic risk increases—the lack of associa-
tion with genetic risk for SCZ or with the added risk for both
disorders was unexpected. Previous research has consistently
shown reduced amygdala volume in SCZ patients compared with
controls, with these studies presenting larger effect sizes than
equivalent studies in BD.5,6 Unlike in the analyses with
globus pallidus, though, the signiﬁcant association betweenT
ab
le
1.
R
es
u
lt
s
fr
o
m
as
so
ci
at
io
n
b
et
w
ee
n
ri
sk
p
ro
ﬁ
le
sc
o
re
(R
PS
)f
o
r
sc
h
iz
o
p
h
re
n
ia
an
d
b
ip
o
la
r
d
is
o
rd
er
ca
se
s
ve
rs
u
s
co
n
tr
o
ls
(S
C
Z
&
B
D
),
sc
h
iz
o
p
h
re
n
ia
ca
se
s
ve
rs
u
s
b
ip
o
la
r
d
is
o
rd
er
ca
se
s
(S
C
Z
vs
B
D
)
an
d
to
ta
l
vo
lu
m
e
in
a
pr
io
ri
se
le
ct
ed
re
g
io
n
s-
o
f-
in
te
re
st
RP
S
P T
Th
al
am
us
β
(P
)
Δ
R
2
H
ip
po
ca
m
pu
s
β
(P
)
Δ
R
2
Am
yg
da
la
β
(P
)
Δ
R
2
G
lo
bu
s
pa
lli
du
s
β
(P
)
Δ
R
2
Ca
ud
at
e
β
(P
)
Δ
R
2
La
te
ra
lv
en
tr
ic
le
s
β
(P
)
Δ
R
2
SC
Z&
BD
1
×
10
−
5
−
0.
07
4
(0
.0
64
)
0.
00
5
0.
03
4
(0
.4
77
)
0.
00
1
−
0.
03
2
(0
.5
15
)
0.
00
1
0.
02
3
(0
.6
50
)
0.
00
1
−
0.
04
3
(0
.4
31
)
0.
00
2
0.
01
0
(0
.8
68
)
o
0.
00
1
1
×
10
−
4
−
0
.0
9
1
(0
.0
2
1
)
0.
0
0
8
0.
00
0
(0
.9
93
)
o
0.
00
1
−
0.
05
6
(0
.2
50
)
0.
00
3
−
0.
09
1
(0
.0
69
)
0.
00
8
−
0.
04
6
(0
.3
96
)
0.
00
2
0.
03
6
(0
.5
30
)
0.
00
1
0.
01
−
0.
02
5
(0
.5
34
)
0.
00
1
−
0.
00
2
(0
.9
71
)
o
0.
00
1
−
0.
06
9
(0
.1
61
)
0.
00
5
−
0
.1
4
9
(0
.0
0
3
)*
0
.0
2
2
−
0.
03
1
(0
.5
70
)
0.
00
1
0.
04
0
(0
.4
86
)
0.
00
2
0.
1
0.
01
7
(0
.6
60
)
o
0.
00
1
0.
01
9
(0
.6
95
)
o
0.
00
1
−
0.
01
8
(0
.7
14
)
o
0.
00
1
−
0
.1
5
1
(0
.0
0
2
)*
0
.0
2
3
0.
00
5
(0
.9
22
)
o
0.
00
1
−
0.
07
6
(0
.1
83
)
0.
00
6
0.
3
0.
02
0
(0
.6
22
)
o
0.
00
1
−
0.
02
7
(0
.5
80
)
0.
00
1
−
0.
02
3
(0
.6
35
)
0.
00
1
−
0
.1
6
2
(0
.0
0
1
)*
0
.0
2
6
0.
01
6
(0
.7
71
)
o
0.
00
1
−
0.
05
9
(0
.3
07
)
0.
00
3
0.
5
0.
02
4
(0
.5
51
)
0.
00
1
−
0.
03
6
(0
.4
57
)
0.
00
1
−
0.
02
1
(0
.6
73
)
o
0.
00
1
−
0
.1
4
4
(0
.0
0
4
)*
0
.0
2
0
−
0.
00
5
(0
.9
25
)o
0.
00
1
−
0.
07
7
(0
.1
78
)
0.
00
6
SC
Zv
sB
D
1
×
10
−
5
−
0.
00
7
(0
.8
54
)
o
0.
00
1
0.
03
7
(0
.4
34
)
0.
00
1
0
.1
0
7
(0
.0
2
9
)*
0
.0
1
1
0.
06
9
(0
.1
66
)
0.
00
5
0.
05
8
(0
.2
81
)
0.
00
3
0.
00
5
(0
.9
30
)
o
0.
00
1
1
×
10
−
4
−
0.
05
0
(0
.2
02
)
0.
00
3
0.
08
8
(0
.0
64
)
0.
00
8
0.
04
6
(0
.3
48
)
0.
00
2
0.
00
0
(0
.9
97
)
o
0.
00
1
0.
03
6
(0
.5
12
)
0.
00
1
0.
00
7
(0
.9
09
)
o
0.
00
1
0.
01
0.
05
7
(0
.1
46
)
0.
00
3
−
0.
00
5
(0
.9
16
)
o
0.
00
1
0.
01
3
(0
.7
97
)
o
0.
00
1
0.
00
2
(0
.9
76
)
o
0.
00
1
−
0.
05
2
(0
.3
35
)
0.
00
3
−
0.
00
6
(0
.9
17
)
o
0.
00
1
0.
1
0.
07
0
(0
.0
78
)
0.
00
5
0.
03
0
(0
.5
36
)
0.
00
1
−
0.
04
2
(0
.3
94
)
0.
00
2
−
0.
03
1
(0
.5
34
)
0.
00
1
0.
05
3
(0
.3
33
)
0.
00
3
−
0.
02
8
(0
.6
29
)
0.
00
1
0.
3
0.
04
6
(0
.2
48
)
0.
00
2
−
0.
00
9
(0
.8
49
)
o
0.
00
1
−
0.
04
9
(0
.3
18
)
0.
00
2
−
0.
01
5
(0
.7
65
)
o
0.
00
1
0.
04
6
(0
.3
98
)
0.
00
2
−
0.
02
2
(0
.6
96
)
o
0.
00
1
0.
5
0.
04
9
(0
.2
17
)
0.
00
2
−
0.
01
1
(0
.8
19
)
o
0.
00
1
−
0.
03
9
(0
.4
31
)
0.
00
1
−
0.
02
8
(0
.5
75
)
0.
00
1
0.
04
9
(0
.3
72
)
0.
00
2
−
0.
01
9
(0
.7
42
)
o
0.
00
1
β
,b
et
a
va
lu
e
fo
r
th
e
R
PS
in
th
e
re
g
re
ss
io
n
eq
u
at
io
n
af
te
r
co
va
ri
at
es
h
av
e
b
ee
n
in
cl
u
d
ed
;P
,s
ig
n
iﬁ
ca
n
ce
le
ve
la
ss
o
ci
at
ed
to
th
e
β
va
lu
e,
al
lP
-v
al
u
es
re
p
o
rt
ed
ar
e
n
o
m
in
al
;Δ
R2
,c
h
an
g
e
in
va
ri
an
ce
ex
p
la
in
ed
ad
d
ed
b
y
th
e
R
PS
.B
o
ld
re
su
lt
s
si
g
n
ify
th
o
se
w
it
h
n
o
m
in
al
P-
va
lu
es
o
0.
05
.A
st
er
is
k
in
d
ic
at
es
th
o
se
w
it
h
p
er
m
u
te
d
P-
va
lu
es
o
0.
05
.
SCZ and BD genetic risk and brain volumes
X Caseras et al
3
Translational Psychiatry (2015), 1 – 5
GRS-SCZvsBD and amygdala volume was limited to one GRS value
(that is, PT 1 × 10
− 5), and to only two GRS values when using the
GRS-BD scores (that is, PT 1 × 10
− 5 and PT 0.01). The limited
number of signiﬁcant associations in this case could suggest the
possibility of these representing a type I error, and further
replication would be required before ﬁrm conclusions can
be drawn.
The lack of association between most subcortical volumes
considered here and GRS for SCZ and BD suggests that the
abnormalities observed in these structures in clinical studies
comparing patients and controls are not a consequence of
disorder liability. Whether they reﬂect environmental exposures
on the causal pathway to disease, or whether they are
consequences of the disorder cannot be answered by the present
study. The fact that some of these abnormalities have been shown
in non-affected relatives of SCZ or BD patients, led to the
conclusion that these were associated with genetic risk. However,
these might well still be explained by shared environmental
factors between patients and their close relatives. For example,
Boos et al.27 showed in a meta-analysis that like patients, non-
affected SCZ relatives showed reduced hippocampal volume
compared with healthy controls. However, it has been recognized
that the family environment of SCZ patients presents with high
levels of stress,28 and that exposure to stress may contribute
to reductions in hippocampal volume via hypercortisolemia.29
Therefore, reduced hippocampal volume in SCZ patients and their
relatives compared with healthy controls with no family history of
SCZ could be explained by differences in the levels of stress to
which these groups are exposed throughout their lives, rather
than to genetic factors.
The report presented here has some strengths and weaknesses
that should be noted. Our sample is large for a study
homogeneous in terms of recruitment methods, exclusion criteria,
magnet, MRI acquisition protocol, data pre-processing, analysis
and quality control. The extent to which this affords a relative
advantage over larger, but much more heterogeneous, meta-
analyses such as those by ENIGMA is, however, not clear. Future
researches with similarly homogeneous but larger samples are
necessary to validate the present ﬁndings. For example, consider-
ing the average correlation found here between volume of lateral
ventricles and the GRS-SCZ&BD (r= 0.1), and to maintain a
nominal P-value of 0.05 and a power of 0.85, a sample size of
n= 717 would be required for that to be signiﬁcant (StatsToDo;
www.statstodo.com/index.php). This is even more relevant with
regard to our conclusion that most previously reported volume
abnormalities are not a consequence of disorder liability, since
Figure 1. Scatterplots representing the signiﬁcant association between volume of the globus pallidus and the shared genetic risk scoring for
schizophrenia and bipolar disorder calculated at different PT levels (top row), and between volume of the amygdala and the non-shared
genetic risk scoring for schizophrenia and bipolar disorder obtained at PT 1 × 10
− 5 (bottom row). BD, bipolar disorder; GRS, genetic risk score;
SCZ, schizophrenia.
Table 2. Results from association between risk proﬁle score (RPS) for
schizophrenia (SCZ) cases versus controls and bipolar disorder (BD)
cases versus controls with total volume in amygdala and globus
pallidus
RPS PT Amygdala β (P) ΔR2 Globus pallidus β (P) ΔR2
SCZ
1× 10− 5 − 0.037 (0.446) 0.001 0.039 (0.434) 0.002
1× 10− 4 − 0.010 (0.837) o0.001 − 0.004 (0.943) o0.001
0.01 − 0.068 (0.168) 0.005 −0.142 (0.004) 0.020
0.1 − 0.018 (0.714) o0.001 − 0.095 (0.056) 0.009
0.3 0.004 (0.937) o0.001 − 0.104 (0.039) 0.011
0.5 0.002 (0.974) o0.001 −0.115 (0.022) 0.013
BD
1× 10− 5 −0.142 (0.004) 0.020 − 0.050 (0.314) 0.003
1× 10− 4 − 0.086 (0.079) 0.007 − 0.020 (0.694) o0.001
0.01 −0.098 (0.045) 0.010 −0.125 (0.012) 0.016
0.1 0.017 (0.724) o0.001 −0.102 (0.042) 0.010
0.3 − 0.016 (0.740) o0.001 − 0.066 (0.188) 0.004
0.5 − 0.043 (0.376) 0.002 −0.066 (0.185) 0.004
β, beta value for the RPS in the regression equation after covariates have
been included; P, signiﬁcance level associated to the β value, all P-values
reported are nominal; ΔR2, change in variance explained added by the RPS.
Bold results signify those with nominal P-valueo0.05.
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lack of association in our study could simply be a consequence of
limited statistical power. Also, as previously stated, due to the lack
of an equivalent GWAS for BD, we based our GRS calculations on
the initial iterations of the PGC data for SCZ.21 Since GRS
estimated from larger GWAS are meant to be more accurate,
our results will require replication once the latest GWAS for BD
results are available. Also, these new GRS would be expected to
present lower variability within healthy control samples, and again
are likely to require larger sample sizes to be powered to reveal
any signiﬁcant association.
In summary, our study reports an association between volume
of the globus pallidus and genetic risk for SCZ and BD, and
suggests this is driven by alleles that confer risk for both disorders.
This result adds further to the possibility that SCZ and BD share a
common genetically driven etiological mechanism in line with the
dimensional focus of the Research Domain Criteria.30 However, we
also found a potential distinct association between genetic risk for
these disorders and amygdala volume, which will also support the
existence of distinct genetically driven etiological mechanism
between SCZ and BD. The latter result, though, was less robust
and requires more cautious consideration. Importantly, our study
also questions whether other repeatedly reported volumetric
abnormalities (for example, enlarged lateral ventricles, reduced
thalamus) are associated with genetic risk for SCZ and/or BD,
rather than being a consequence of the disease or of the exposure
to environmental factors.
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